Form 4: Cytek Biosciences Executive Yan Ming Reports Stock Transactions
SEC Form 4 Filing
Cytek Biosciences' Chief Technology Officer, Yan Ming, reports the vesting of restricted stock units and subsequent tax withholding, resulting in adjustments to beneficial ownership of common stock.
Summary
- On August 19, 2024, Yan Ming, Chief Technology Officer of Cytek Biosciences, Inc., engaged in transactions involving restricted stock units (RSUs) and common stock.
- These transactions included the vesting of RSUs and the surrender of shares to cover tax withholding obligations.
- Specifically, 1,981, 7,363, and 5,525 RSUs vested, converting into common stock.
- A total of 588, 1,797, and 1,346 shares were withheld by the issuer to satisfy tax obligations at a price of $5.53 per share.
- Following these transactions, Yan Ming's directly held beneficial ownership of common stock is 6,007,075 shares and 79,193 RSUs.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions, with no inherent positive or negative implications for the company's performance.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding insider transactions.
Stakeholder Impact
- Shareholders are informed about executive stock transactions, promoting transparency.
- Employees may be impacted by the vesting schedules of their own stock-based compensation.
Key Dates
| Date | Description |
|---|---|
| 08/19/2024 | Date of transactions involving RSUs vesting and tax withholding. |
| 08/21/2024 | Date of filing the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.